Physician profile
Daniel Witten
NPI 1245233782
$1,086.80
in general payments reported to CMS, 2019-2025
19 companies · $21.49 in 2025
The $21.49 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.49 · 2022: $87.92 · 2023: $221 · 2024: $709 · 2025: $21.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $951.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $198.30 | 2022-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $181.42 | 2024 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $118.27 | 2022-2024 | Mounjaro |
| Astellas Pharma US INC | $94.48 | 2023-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $73.13 | 2024 | |
| Viiv Healthcare Company | $68.71 | 2024 | Apretude |
| Amgen INC. | $64.35 | 2024-2025 | Repatha, Otezla, Repatha |
| Scilex Pharmaceuticals INC. | $47.49 | 2019 | |
| Aimmune Therapeutics, INC. | $36.10 | 2024 | |
| Janssen Pharmaceuticals, INC | $33.88 | 2024 | Xarelto |
| Pfizer INC. | $26.31 | 2023 | |
| Sunovion Pharmaceuticals INC. | $21.22 | 2022 | |
| Esperion Therapeutics, INC. | $20.06 | 2024 | Nexletol |
| Supernus Pharmaceuticals, INC. | $19.63 | 2023 | Qelbree |
| Merck Sharp & Dohme LLC | $18.80 | 2024 | Gardasil 9, Gardasil, M-M-R II |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $17.10 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.67 | 2024 | Quviviq |
| Dexcom, INC. | $16.14 | 2023 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $14.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Witten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.